Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for CCXI, PCT and WISH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Thursday, 10 June 2021 10:10 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CCXI Shareholders Click Here: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16766&wire=1
PCT Shareholders Click Here: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=16766&wire=1
WISH Shareholders Click Here: https://www.zlk.com/pslra-1/contextlogic-inc-loss-submission-form?prid=16766&wire=1
 

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Thursday, June 10, 2021, Press release picture

ChemoCentryx, Inc. (NASDAQ: CCXI)

CCXI Lawsuit on behalf of: investors who purchased November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline : July 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16766&wire=1

According to the filed complaint, during the class period, ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

PureCycle Technologies, Inc. (NASDAQ: PCT)

PCT Lawsuit on behalf of: investors who purchased November 16, 2020 - May 5, 2021
Lead Plaintiff Deadline : July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=16766&wire=1
According to the filed complaint, during the class period, PureCycle Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contextlogic Inc. (NASDAQ: WISH)

This lawsuit is on behalf of investors who purchased WISH pursuant or traceable to the registration statement and prospectus issued in connection with ContextLogic's December 16, 2020 initial public stock offering or between December 16, 2020 and May 12, 2021.
Lead Plaintiff Deadline : July 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/contextlogic-inc-loss-submission-form?prid=16766&wire=1

In the registration statement and prospectus used to conduct the initial public offering and throughout the class period, defendants made materially false and misleading statements about the strength of ContextLogic's business operations and financial prospects by overstating its then-present monthly active users ("MAUs") and MAU growth trends.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: